Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection

J Immunol. 2002 Jan 1;168(1):1-4. doi: 10.4049/jimmunol.168.1.1.

Abstract

IL-10 has potent immunosuppressive properties, and IL-10-producing CD4+ Tr1 cells have been characterized as regulators of Th1-mediated immunity. In this study, using a s.c. model of glioma cell growth in mice, we demonstrate that CD4+, but not CD8+, T cells play a critical role in tumor rejection following vaccination with irradiated glioma cells. Surprisingly, glioma-specific CD4+ T cells produce IL-10 but neither IL-4 nor IFN-gamma, and glioma rejection is compromised in IL-10(-/-) hosts. Hence, our findings demonstrate that IL-10-producing CD4+ T cells can manifest antitumor functions and suggest that IL-10 may have proinflammatory effects in disease states.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Neoplasms / immunology*
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy
  • CD4-Positive T-Lymphocytes / immunology*
  • Cell Division
  • Cells, Cultured
  • Cytokines / biosynthesis
  • Cytokines / genetics
  • Disease-Free Survival
  • Glioma / immunology*
  • Glioma / pathology
  • Glioma / therapy
  • Interleukin-10 / biosynthesis*
  • Interleukin-10 / genetics
  • Interleukin-10 / physiology*
  • Kinetics
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neoplasm Transplantation
  • RNA, Messenger / biosynthesis
  • Remission Induction
  • T-Lymphocytes, Cytotoxic / immunology
  • Tumor Cells, Cultured
  • Up-Regulation

Substances

  • Cytokines
  • RNA, Messenger
  • Interleukin-10